所有图片(1)
别名:
Thiodigalactoside, β-D-Galactopyranosyl 1-thio-β-D-galactopyranoside, D-Galactopyranosylthio-β-D-galactopyranoside, TDG, D-Galactopyranosyl-β-D-thiogalactopyranoside
经验公式（希尔记法）:
C12H22O10S
推荐产品
检测方案
≥98% (HPLC)
形式
powder
颜色
white to beige
溶解性
H2O: 2 mg/mL, clear
储存温度
−20°C
生化/生理作用
Thiodigalactoside (TDG)is a potent inhibitor of galectin-1 (GAL1) that suppress tumor growth by inhibiting multiple cancer enhancing activities of galectin-1, including immune cell dysregulation, angiogenesis and protection against oxidative stress. Thiodigalactoside reverses galectin-1-induced cisplatin resistance in HCC cells. Thiodigalactoside significantly reduces body weight gain in diet-induced obese rats.
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
S Aggarwal et al.
Oral diseases, 22(5), 445-453 (2016-03-24)
Thiodigalactoside (TDG), a synthetic inhibitor of β-galactoside-binding protein (β-GBP) suppresses tumour growth by inhibiting multiple cancer enhancing activities of β-GBP. Hence, we attempted to understand whether disruption of β-GBP functions and indirect inhibition of Treg cells by TDG affect the
Yu-Chi Su et al.
PloS one, 11(2), e0148408-e0148408 (2016-02-10)
Hepatocellular carcinoma (HCC) is one of the most common cancers in Taiwan. Although chemotherapy is the primary treatment for HCC patients, drug resistance often leads to clinical failure. Galectin-1 is a beta-galactoside binding lectin which is up-regulated in HCC patients
Isabel Pablos et al.
Cell reports, 37(4), 109892-109892 (2021-10-22)
The main viral protease (3CLpro) is indispensable for SARS-CoV-2 replication. We delineate the human protein substrate landscape of 3CLpro by TAILS substrate-targeted N-terminomics. We identify more than 100 substrates in human lung and kidney cells supported by analyses of SARS-CoV-2-infected
Hilal Ahmad Parray et al.
International journal of molecular sciences, 16(7), 14441-14463 (2015-06-30)
Previously, galectin-1 (GAL1) was found to be up-regulated in obesity-prone subjects, suggesting that use of a GAL1 inhibitor could be a novel therapeutic approach for treatment of obesity. We evaluated thiodigalactoside (TDG) as a potent inhibitor of GAL1 and identified
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门